ADAM9

ADAM9 Informations sur la molécule

Nom anglaisDisintegrin and metalloproteinase domain-containing protein 9Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3Alias de la cibleMeltrin-gamma,ADAM Metallopeptidase Domain 9 (Meltrin Gamma),Cellular disintegrin-related protein,ADAM 9,Metalloprotease/disintegrin/cysteine-rich protein 9,Mltng,MDC9,KIAA0021,Meltrin Gamma,CORD9,A Disintegrin And Metalloproteinase Domain 9 (Meltrin Gamma),ADAM Metallopeptidase Domain 9,Cone Rod Dystrophy 9,MCMP,Myeloma cell metalloproteinase
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisDisintegrin and metalloproteinase domain-containing protein 9
Alias de la cibleMeltrin-gamma,ADAM Metallopeptidase Domain 9 (Meltrin Gamma),Cellular disintegrin-related protein,ADAM 9,Metalloprotease/disintegrin/cysteine-rich protein 9,Mltng,MDC9,KIAA0021,Meltrin Gamma,CORD9,A Disintegrin And Metalloproteinase Domain 9 (Meltrin Gamma),ADAM Metallopeptidase Domain 9,Cone Rod Dystrophy 9,MCMP,Myeloma cell metalloproteinase
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3
Phase de R&D la plus avancéePhase 2 Clinical

ADAM9Contexte de la molécule

ADAM9 (A disintegrin and a metalloprotease 9) is a membrane-anchored protein that participates in a variety of physiological functions, primarily through the disintegrin domain for adhesion and the metalloprotease domain for ectodomain shedding of a wide variety of cell surface proteins. ADAM9 influences the developmental process, inflammation, and degenerative diseases.Recently, increasing evidence has shown that ADAM9 plays an important role in tumor biology. Overexpression of ADAM9 has been found in several cancer types and is correlated with tumoraggressiveness and poor prognosis. In addition, through either proteolytic or non-proteolytic pathways, ADAM9 promotes tumor progression, therapeutic resistance, and metastasis of cancers.Therefore, comprehensively understanding the mechanism of ADAM9 is crucial for the development of therapeutic anti-cancer strategies. In this review, we summarize the current understanding of ADAM9 in biological function, pathophysiological diseases, and various cancers. Recent advances in therapeutic strategies using ADAM9-related pathways are presented as well.

ADAM9Alias de la molécule

Disintegrin and metalloproteinase domain-containing protein 9 (EC:3.4.24.-) Cellular disintegrin-related protein,Meltrin-gamma,Metalloprotease,disintegrin,cysteine-rich protein 9,Myeloma cell metalloproteinase,ADAM9,KIAA0021, MCMP, MDC9, MLTNG

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
Izeltabart tapatansineIMGC-936Phase 2 ClinicalImmunogen IncSolid tumours
Details
DB-1317DB-1317Phase 1 ClinicalDuality Biologics (Suzhou) Co LtdNeoplasm Metastasis; Solid tumours
Details
MGC-028MGC028; MGC-028Phase 1 ClinicalMacrogenics IncCarcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours
Details
  • Liste de produits
  • Informations sur les médicaments cliniques